Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jennifer L. Culbertson"'
Publikováno v:
TechTrends. 64:678-679
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f47adfe39e4ae7b77491aecfe80b45b0
https://doi.org/10.1007/s11528-020-00507-2
https://doi.org/10.1007/s11528-020-00507-2
Autor:
Gary M. Clark, Denni M. Zborowski, Lesley Seymour, Michelle Savoie, Jennifer L. Culbertson, Marlo Whitehead, Frances A. Shepherd
Publikováno v:
Journal of Thoracic Oncology. 1:837-846
Introduction Erlotinib (Tarceva®) has demonstrated a survival benefit in unselected patients with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy. Because not all patients benefit from erlotinib, epidermal growth factor rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a1ae944ad1174aa93f562e4cd6dd113
https://doi.org/10.1097/01243894-200610000-00013
https://doi.org/10.1097/01243894-200610000-00013
Autor:
Gary M, Clark, Denni M, Zborowski, Jennifer L, Culbertson, Marlo, Whitehead, Michelle, Savoie, Lesley, Seymour, Frances A, Shepherd
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 1(8)
Erlotinib (Tarceva) has demonstrated a survival benefit in unselected patients with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy. Because not all patients benefit from erlotinib, epidermal growth factor receptor (EGFR) pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7555540c72dd22a04712e2477a46135d
https://pubmed.ncbi.nlm.nih.gov/17409968
https://pubmed.ncbi.nlm.nih.gov/17409968